Table 4.
Effects of asenapine and olanzapine on 5-CSR task performance under standard or difficult conditions
| Correct (%) | Omissions,% | Total trials | CR latency (ms) | IR latency (ms) | CP latency (ms) | |
|---|---|---|---|---|---|---|
| Standard paradigm | ||||||
| Asenapine (mg/kg s.c.) | ||||||
| Vehicle | 88.3 ± 1.7 | 8.3 ± 1.5 | 264 ± 8 | 527 ± 31 | 1,099 ± 74 | 1,655 ± 172 |
| 0.003 | 88.5 ± 1.9 | 8.7 ± 1.5 | 264 ± 8 | 532 ± 40 | 1,132 ± 101 | 1,619 ± 135 |
| 0.01 | 88.2 ± 1.6 | 9.3 ± 2.0 | 268 ± 8 | 522 ± 25 | 1,125 ± 56 | 1,635 ± 133 |
| 0.03 | 87.9 ± 1.4 | 10.4 ± 1.9 | 262 ± 7 | 532 ± 30 | 1,066 ± 108 | 1,644 ± 119 |
| NS | NS | NS | NS | NS | NS | |
| Olanzapine (mg/kg s.c.) | ||||||
| Vehicle | 86.0 ± 1.5 | 7.8 ± 0.9 | 261 ± 9 | 510 ± 20 | 1,130 ± 90 | 1,410 ± 100 |
| 0.03 | 84.1 ± 1.7 | 6.4 ± 1.1 | 263 ± 6 | 510 ± 20 | 970 ± 80 | 1,480 ± 110 |
| 0.1 | 86.9 ± 1.8 | 8.5 ± 0.8 | 261 ± 9 | 510 ± 20 | 1,230 ± 150 | 1,550 ± 120 |
| 0.3 | 86.9 ± 1.3 | 15.8 ± 2.1**** | 246 ± 10** | 520 ± 20 | 1,510 ± 240**** | 1,550 ± 80 |
| NS | F(3,133) = 18.83, P < 0.0001 | F(3,133) = 3.40, P = 0.02 | NS | F(3,133) = 958, P < 0.0001 | NS | |
| Difficult paradigm | ||||||
| Asenapine (mg/kg s.c.) | ||||||
| Vehicle | 71.0 ± 1.7 | 13.9 ± 3.6 | 240 ± 8 | 480 ± 18 | 929 ± 57 | 1,539 ± 109 |
| 0.003 | 71.2 ± 2.6 | 12.3 ± 3.3 | 239 ± 8 | 477 ± 17 | 927 ± 47 | 1,508 ± 104 |
| 0.01 | 72.1 ± 2.4 | 15.1 ± 4.4 | 242 ± 8 | 511 ± 26 | 1,016 ± 58 | 1,582 ± 104 |
| 0.03 | 72.9 ± 1.3 | 19.2 ± 5.1*** | 224 ± 12** | 516 ± 33 | 1,080 ± 66* | 1,558 ± 92 |
| NS | F(3,209) = 8.14, P < 0.0001 | F(3,209) = 6.62, P < 0.0001 | NS | F(3,209) = 3.93, P = 0.001 | NS | |
| Asenapine (mg/kg s.c.) | ||||||
| Vehicle | 73.6 ± 2.4 | 12.3 ± 4.4 | 231 ± 16 | 507 ± 26 | 1,019 ± 59 | 1,561 ± 118 |
| 0.03 | 69.3 ± 2.6 | 12.9 ± 3.4 | 230 ± 10 | 519 ± 15 | 1,092 ± 52 | 1,587 ± 122 |
| 0.1 | 65.0 ± 3.2**** | 21.9 ± 3.5** | 187 ± 13**** | 529 ± 24 | 1,115 ± 71 | 1,594 ± 115 |
| 0.3 | 66.3 ± 4.2 | 39.7 ± 5.9**** | 97 ± 26**** | 521 ± 33*** | 1,446 ± 151**** | 2,813 ± 1,064 |
| F(3,209) = 6.45, P < 0.0001 | F(3,209) = 40.01, P < 0.0001 | F(3,209) = 62.69, P < 0.0001 | F(3,209) = 6.03, P = 0.001 | F(3,209) = 5.31, P = 0.002 | NS | |
| Olanzapine (mg/kg s.c.) | ||||||
| Vehicle | 73.16 ± 1.7 | 8.9 ± 1.3 | 251 ± 6 | 481 ± 21 | 1,015 ± 97 | 1,466.3 ± 114 |
| 0.03 | 68.44 ± 1.2** | 10.9 ± 1.3 | 239 ± 7** | 517 ± 36 | 977 ± 81 | 1,500.1 ± 121 |
| 0.1 | 70.54 ± 2.2 | 13.7 ± 3.0** | 237 ± 13*** | 508 ± 35 | 987 ± 88 | 1,500.5 ± 117 |
| 0.3 | 67.4 ± 2.2** | 17.3 ± 4.4**** | 216 ± 15**** | 492 ± 25 | 1,117 ± 88 | 1,607.1 ± 179 |
| F(3,189) = 3.77, P = 0.012 | F(3,189) = 11.05, P < 0.0001 | F(3,189) = 15.96, P < 0.0001 | NS | NS | F(3,189) = 3.04, P = 0.03 | |
| Risperidone (mg/kg s.c.) | ||||||
| Vehicle | 71.1 ± 1.8 | 13.9 ± 3.6 | 241 ± 8 | 480 ± 18 | 929 ± 57 | 1,539 ± 109 |
| 0.01 | 71.3 ± 2.6 | 12.3 ± 3.3 | 239 ± 8 | 477 ± 17 | 927 ± 47 | 1,508 ± 104 |
| 0.03 | 72.1 ± 2.5 | 15.1 ± 4.4*** | 242 ± 8* | 511 ± 26 | 1,016 ± 58** | 1,582 ± 104* |
| 0.1 | 73.0 ± 1.3 | 19.2 ± 5.1*** | 224 ± 12**** | 516 ± 33**** | 1,080 ± 66**** | 1,558 ± 92 |
| F(3,269) = 7.68, P < 0.0001 | F(3,269) = 6.95, P < 0.0001 | F(3,269) = 6.15, P < 0.0001 | F(3,269) = 9.03, P < 0.0001 | F(3,269) = 2.93, P = 0.034 | ||
Standard paradigm: stimulus duration of cue light = 0.25 s. Difficult paradigm: stimulus duration of cue light = 0.5 s. Data are mean ± SEM.
5-CSR 5-choice serial reaction, CP collect pellet, CR correct response, IR incorrect response, s.c. subcutaneous
“”*P < 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P < 0.0001 (Dunnett’s test vs vehicle)